Currently, Huya’s novel anti-arrhythmic compound HBI-3000 is under development in both China and the US.
Huya CTO and COO China Clement Gingras said the alliance with Zhejiang Chinese Medical University Life Science College will further strengthen Huya’s collaborative efforts with the faculty and researchers of the university.
"Together, Huya and Zhejiang Chinese Medical University Life Science College will help advance the progression of TCM to the global markets, benefiting patients worldwide," Gingras said.